Med. praxi. 2018;15(4):211-214 | DOI: 10.36290/med.2018.039

Arterial hypertension and pulse pressure

MUDr. Marek Vícha, doc. MUDr. Jan Václavík, Ph.D., FESC
I. interní klinika – kardiologická, FN a LF UP Olomouc

Arterial hypertension is one of the most frequent diseases in outpatient clinical practice and also the most important risk factor forcoronary heart disease, stroke, heart failure, end-stage renal disease or atrial fibrillation. It is defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥ 90 mmHg on repeated office measurements. Pulse pressure is defined as the systolicminus the diastolic blood pressure. It is a good predictor of cardiovascular events among older adult patients and the value ≥ 60mmHg is regarded as asymptomatic organ damage. The main goal of therapy is to reach target blood pressure and its benefitis largely independent of the drugs employed. The current Guidelines ESH/ESC 2013 confirm that all classes of antihypertensivedrugs are all suitable for the initiation and maintenance of antihypertensive treatment.

Keywords: arterial hypertension, guidelines, target blood pressure values, pharmacotherapy, pulse pressure

Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vícha M, Václavík J. Arterial hypertension and pulse pressure. Med. praxi. 2018;15(4):211-214. doi: 10.36290/med.2018.039.
Download citation

References

  1. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013; 31(10): 1925-1938. Go to original source... Go to PubMed...
  2. Widimský J jr., Filipovský J, Ceral J, et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze 2017. Hypertenze a kardiovaskulární prevence. Česká společnost pro hypertenzi. Praha, TARGET-MD s.r.o., 2018, Supplementum, Dostupné z: http://www.hypertension.cz
  3. Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA. Cor Vasa. 2011; 53; 220-229. Go to original source...
  4. Táborský M, et al. Kardiologie pro interní praxi. Praha: Mladá fronta, 2014: 296 s.
  5. Táborský M, Kautzner J, Linhart A, et al. Kardiologie. Praha: Mladá fronta, 2017: 1294 s.
  6. ACCOMPLISH Trial Investigators, Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23): 2417-2428. Go to original source... Go to PubMed...
  7. Václavík J. Obtížně léčitelná hypertenze. Druhé, doplněné a přepracované vydání. Praha: Mladá fronta, 2017: 136 s.
  8. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, et al. Telmisartan, ramipril, or both in patiens at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547-1559. Go to original source... Go to PubMed...
  9. Raymond R. Townsend. Increased pulse pressure. In: Uptodate.com [online]. [cit. 20-12-2017]. Dostupné z: https://www.uptodate.com/contents/increased-pulse-pressure
  10. Franklin SS, Gustin W 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997; 96(1): 308. Go to original source...
  11. Bavishi CH, et al. Isolated Systolic Hypertension: An Update After SPRINT The American Journal of Medicine; 129(12): 1251-1258. Go to original source...
  12. Clara JG, De Macedo ME, Pego M. Prevalence of isolated systolic hypertension in the population over 55 years old. Results from a national study. Rev Port Cardiol. 2007; 26(1): 11-18. PubMed PMID: 17427833. Go to PubMed...
  13. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002; 287: 1003-1010. Go to original source... Go to PubMed...
  14. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation. 1999; 100(4): 354. Go to original source...
  15. Yasuno S, Ueshima K, Oba K, Fujimoto A, et al. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care. 2010; 33(5): 1122. Epub 2010 Feb 25. Go to original source...
  16. Mul? G, Nardi E, Cottone S, et al. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am J Hypertens. 2007; 20(2): 197. Go to original source...
  17. Rimoldi SF, Messerli FH, Chavez P, et al. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich). 2015; 17(3): 193-199. Go to original source... Go to PubMed...
  18. LIFE Study Group. Fyhrquist F, Dahlöf B, Devereux RB, et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 2005; 45(4): 580. Go to original source... Go to PubMed...
  19. REASON Project Investigators. London GM, Asmar RG, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004; 43(1): 92. Go to original source...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.